Coxsackie B

style="background:#Template:Taxobox colour;"|Coxsackie B virus
Coxsackie B4 virus Coxsackie B4 virus
style="background:#Template:Taxobox colour;" | Virus classification
Group: Group IV ((+)ssRNA) Family: Picornaviridae Genus: Enterovirus Species: Human enterovirus B
Subtype
Coxsackie B virus

WikiDoc Resources for Coxsackie B
Articles
Most recent articles on Coxsackie B Most cited articles on Coxsackie B Review articles on Coxsackie B Articles on Coxsackie B in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Coxsackie B Images of Coxsackie B Photos of Coxsackie B Podcasts & MP3s on Coxsackie B Videos on Coxsackie B
Evidence Based Medicine
Cochrane Collaboration on Coxsackie B Bandolier on Coxsackie B TRIP on Coxsackie B
Clinical Trials
Ongoing Trials on Coxsackie B at Clinical Trials.gov Trial results on Coxsackie B Clinical Trials on Coxsackie B at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Coxsackie B NICE Guidance on Coxsackie B NHS PRODIGY Guidance FDA on Coxsackie B CDC on Coxsackie B
Books
Books on Coxsackie B
News
Coxsackie B in the news Be alerted to news on Coxsackie B News trends on Coxsackie B
Commentary
Blogs on Coxsackie B
Definitions
Definitions of Coxsackie B
Patient Resources / Community
Patient resources on Coxsackie B Discussion groups on Coxsackie B Patient Handouts on Coxsackie B Directions to Hospitals Treating Coxsackie B Risk calculators and risk factors for Coxsackie B
Healthcare Provider Resources
Symptoms of Coxsackie B Causes & Risk Factors for Coxsackie B Diagnostic studies for Coxsackie B Treatment of Coxsackie B
Continuing Medical Education (CME)
CME Programs on Coxsackie B
International
Coxsackie B en Espanol Coxsackie B en Francais
Business
Coxsackie B in the Marketplace Patents on Coxsackie B
Experimental / Informatics
List of terms related to Coxsackie B

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

To go back to Coxsackie virus home page, click here.

Overview

Coxsackie B is the name of a group of six serotypes of pathogenic enteroviruses that trigger illness ranging from mild gastrointestinal distress to full-fledged pericarditis, myocarditis, pericardial effusion, pleurodynia and hepatitis.

Viral Structure and Function

Coxsackie B viruses are single-strange positive-sense RNA viruses that are resistant to a wide variety of chemical treatments. The viral particles themselves are roughly 30nm icosahedrons. The virus is most frequently distributed via the fecal-oral route, and infection commonly occurs after eating contaminated food. Coxsackie B viruses are cytolytic, and Coxsackie B2 and B5 viruses have been implicated in hand, foot and mouth disease as well as respiratory infection. Infection in infants is mostly asymptomatic, but sometimes results in the death of the infant, often due to myocarditis. Birth defects may also be present in a coxsackie B infected infant.

Associated Conditions

• The B4 strain of coxsackie viruses has been discovered to be a possible cause of Diabetes mellitus type 1.
• Sjogren's syndorme is also thought to have a connections with coxsackie B virus.
• Coxsackie B3 and B4 are related to acute flaccid myelitis.

Epidemiology and Demographics

The various members of the Coxsackie B group were discovered almost entirely in the United States, appearing originally in Connecticut, Ohio, New York, and Kentucky, although a sixth member of the group has been found in the Philippines. That said, all six serotypes have a global distribution and are a relatively common cause of gastrointestinal upset.

Diagnosis

History and Symptoms

Symptoms of infection with viruses in the Coxsackie B grouping include fever, headache, sore throat, gastrointestinal distress, as well as chest and muscle pain. This presentation is known as pleurodynia or Bornholmes disease in many areas. Patients with chest pain should see a doctor immediately as it can progress to myocarditis or pericarditis, which result in permanent heart damage or death. Coxsackie B virus infection may also induce aseptic meningitis. As a group, they are the most common cause of unexpected sudden death, and may account for up to 50% of such cases. The incubation period for the Coxsackie B viruses is, like most of the Enteroviridae, highly variable, ranging from 2 to 35 days, and illness may last for up to two weeks, but may resolve as quickly as two days. Infection usually occurs between the months of June and October.

Laboratory Findings

Enterovirus infection is diagnosed mainly via serological tests such as ELISA and from cell culture. Because the same level and type of care is given regardless of type of Coxsackie B infection, it is mostly unnecessary for treatment purposes to diagnose which virus is causing the symptoms in question, though it may be epidemiologically useful.

Treatment

Medical Therapy

As of 2007, there is no treatment for the Coxsackie B group of viruses. Pallative care is available, however, and patients suffering chest pain or stiffness of the neck should be examined for signs of cardiac or central nervous system involvement, respectively. Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious. Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced myocarditis or pericarditis, antiinflammatories can be given to reduce damage to the heart muscle. There is no vaccine for any member of the group.

Prevention

Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious. Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced myocarditis or pericarditis,antiinflammatories can be given to reduce damage to the heart muscle. There is no vaccine for any member of the group.